shengnuo biotechnology announced the quarterly report for the first quarter of 2022, actively promoting the layout of peptide medical beauty

1、In addition to the steady growth of performance and various indicators

2、shengnuo biotechnology has completed the preliminary layout of peptide medical beauty products, and the current situation of lack of domestic terminal peptide medical beauty products may be Usher in a new situation.

According to the 2022 first quarter quarterly report of shengnuo biotechnology, the company achieved operating income of 80.7448 million yuan, net profit of 14.2929 million yuan, a year-on-year increase of 22.64%, and basic earnings per share of 0.18 yuan. The non-net profit deducted in a single quarter was 12.1321 million yuan, a year-on-year increase of 2.79%; the debt ratio was 19.43%, the investment income was 1.0955 million yuan, the financial expenses were -396,300 yuan, and the gross profit rate was 67.32%.

In addition to the steady growth of performance and various indicators, what is more worthy of attention is the two foreign investments of shengnuo biotechnology in the first quarter.

One of the investments is the investment of Chengdu Shengrong Netac Technology Co., Ltd. (hereinafter referred to as Shengrong Netac). According to the foreign investment capital increase proposal reviewed and approved by the company’s board of directors on March 2, 2022, Shengrong Netac, a wholly-owned subsidiary of Shengnuo Bio, will use the RMB 24,500,000 subscribed for the newly added registered capital of RMB 4,900,000 of Guangzhou Shengjing Shangmei Biotechnology Co., Ltd. (hereinafter referred to as Guangzhou Shengjing), accounting for 49% of the total share capital of Guangzhou Shengjing after the capital increase.

The capital increase agreement has been signed and the capital contribution will be completed on March 11, 2022. Guangzhou Shengjing’s main business is: providing a full range of peptide medical beauty products and services, and has its own brand products and formulas. shengnuo biotechnologylogical will also provide raw materials for it in the early stage.

The other is the subscription of the newly added registered capital of Chengdu Gechun Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as Chengdu Gechun). Shengrong Netac, a wholly-owned subsidiary, subscribed for an additional registered capital of RMB 225,000 of Chengdu Gechun Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as Chengdu Gechun) for RMB 15,000,000, accounting for 13.0434% of the total share capital of Chengdu Gechun after the capital increase.

The capital increase agreement has been signed and the capital contribution will be completed on March 11, 2022. Chengdu Gechun’s main business is: research and development of APIs, pharmaceutical intermediates, cosmetic raw materials, and food additives; research on authentic Chinese medicinal materials, preclinical research on various innovative natural medicines, and establishment of a library of plant monomer compounds;

Natural product intermediates, chemical components of traditional Chinese medicines, reference substances of traditional Chinese medicines, natural product extracts, etc. for high-purity new drug research and development.

From the information on medical beauty investment disclosed in the 2021 shengnuo biotechnologylogical enterprise annual report, to the landing feedback in the company’s first-quarter quarterly report, shengnuo biotechnology has completed the preliminary layout of peptide medical beauty products, and the current situation of lack of domestic terminal peptide medical beauty products may be Usher in a new situation.

Relying on the expansion of the peptide new crown specific drug track and the layout of medical beauty peptides, shengnuo biotechnology is expected to bring more benefits to the deeper application and industry development of the domestic peptide field.